Bottom Line: People who survived childhood cancer were more than twice as likely as the general population to have high blood pressure (hypertension) as adults.
Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Author: Todd M. Gibson, PhD, assistant faculty member in the Epidemiology/Cancer Control department at St. Jude Children's Research Hospital in Memphis, Tennessee.
Background: Improvements in treatment have dramatically increased survival rates from pediatric cancers, with about 83 percent of children surviving at least five years and many becoming long-term survivors. Today, an estimated 420,000 Americans are adult survivors of childhood cancer.
However, many suffer long-term side effects. "High blood pressure is an important modifiable risk factor that increases risk of heart problems in everyone. Research has shown that high blood pressure can have an even greater negative impact on survivors of childhood cancer who were treated with cardiotoxic therapies such as anthracyclines or chest radiation," Gibson said.
How the Study Was Conducted and Results: To assess the prevalence of high blood pressure among survivors of childhood cancer, Gibson and colleagues examined 3,016 adults who were part of the St. Jude Lifetime Cohort Study, which provides ongoing medical assessments of childhood cancer survivors to advance knowledge of their long-term health outcomes. Participants were considered to have high blood pressure if their systolic blood pressure was 140 or greater, their diastolic blood pressure was 90 or greater, or if they had been previously diagnosed with hypertension and were taking antihypertensive medication.
The study showed that the prevalence of hypertension was 2.6 times higher among childhood cancer survivors than expected, based on age-, sex-, race- and body mass index-specific rates in the general population.
The prevalence of hypertension increased over time: At age 30, 13 percent of the survivors had hypertension; at 40, 37 percent had hypertension, and by age 50, more than 70 percent of the survivors had hypertension. Gibson said the prevalence of hypertension in cancer survivors matched rates in the general population of people about a decade older.
Certain groups of survivors were the most likely to have hypertension: men; non-Hispanic blacks, older survivors, and those who were overweight or obese, the study showed.
The study found that exposure to radiotherapy or chemotherapy were not significantly associated with hypertension.
Author Comment: Gibson said the lack of association between high blood pressure and radiotherapy and chemotherapy was surprising, and suggests that the connection between childhood cancer survival and adult hypertension is multifactorial and worthy of future research. In the meantime, he said, clinicians should be mindful that survivors of childhood cancer are more likely than the general public to develop high blood pressure.
"The good news is that, unlike prior cancer therapy, high blood pressure is a modifiable risk factor," Gibson noted. "Research is needed to identify effective interventions to prevent hypertension in survivors, but our results emphasize the importance of blood pressure surveillance and management."
Limitations: Gibson said a limitation of the study is that it was based on blood pressure measurements that were taken at a single study visit. A clinical diagnosis of hypertension typically requires measurements taken at multiple intervals, he explained. Also, Gibson added, the St. Jude Lifetime Cohort is a group of cancer survivors who undergo frequent clinical follow-up, so its participants may have benefited from being monitored and may, therefore, be in better health than survivors who have less comprehensive follow-up.
###
To interview Todd Gibson, contact Julia Gunther at [email protected] or 215-446-6896.
Funding & Disclosures: The study was funded by the National Cancer Institute and the American Lebanese Syrian Associated Charities. Gibson declares no conflicts of interest.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 21,900 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.
Media Contact
Lauren Riley
[email protected]
215-446-7155
@aacr
